Chronic hepatitis E in a patient with Burkitt’s lymphoma
- Authors: Ilchenko L.Y.1,2,3, Asadi Mobarkhan F.A.1,4, Karlsen A.A.1, Potemkin I.A.1,4, Malinnikova E.Y.1,4, Kyuregyan K.K.1,4, Mikhailov M.I.1,4
-
Affiliations:
- I.I. Mechnikov Scientific Research Institute of Vaccines and Serums
- N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia
- M.P. Chumakov Federal Scientific Center of RAS for Research and Development of Immunobiological Preparations
- Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia
- Issue: Vol 8, No 3 (2022)
- Pages: 109-115
- Section: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/288942
- DOI: https://doi.org/10.18565/therapy.2022.3.109-115
- ID: 288942
Cite item
Abstract
Full Text
About the authors
Lyudmila Yu. Ilchenko
I.I. Mechnikov Scientific Research Institute of Vaccines and Serums; N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia; M.P. Chumakov Federal Scientific Center of RAS for Research and Development of Immunobiological Preparations
Email: ilchenko-med@yandex.ru
Dr. med. habil., professor, leading researcher at the Laboratory of viral hepatitis; professor of the Department of hospital therapy named after G.I. Storozhakov of the Faculty of general medicine; leading researcher at the Laboratory for modeling immunobiological processes
Fedor A. Asadi Mobarkhan
I.I. Mechnikov Scientific Research Institute of Vaccines and Serums; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia
Email: 1amfa@bk.ru
researcher at Research Institute of Molecular and Personalized Medicine; researcher at the Laboratory of viral hepatitis
Anastasia A. Karlsen
I.I. Mechnikov Scientific Research Institute of Vaccines and Serums
Email: karlsen12@gmail.com
researcher at Research and Educational Resource Center «High-Performance Methods of Genomic Analysis»
Ilya A. Potemkin
I.I. Mechnikov Scientific Research Institute of Vaccines and Serums; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia
Email: axi0ma@mail.ru
PhD in Medicine, researcher at the Department of viral hepatitis studies, Research Institute of Molecular and Personalized Medicine
Elena Yu. Malinnikova
I.I. Mechnikov Scientific Research Institute of Vaccines and Serums; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia
Email: malinacgb@mail.ru
Dr. med. habil., professor, head of the Department of virology; leading researcher at the Laboratory of viral hepatitis
Karen K. Kyuregyan
I.I. Mechnikov Scientific Research Institute of Vaccines and Serums; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia
Email: karen-kyuregyan@yandex.ru
Dr. habil. biol., professor of RAS, chief researcher at Research Institute of Molecular and Personalized Medicine
Mikhail I. Mikhailov
I.I. Mechnikov Scientific Research Institute of Vaccines and Serums; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia
Email: michmich2@yandex.ru
Dr. med. habil., professor, corresponding member of RAS, scientific director of Research Institute of Molecular and Personalized Medicine; head of the Laboratory of viral hepatitis
References
- Balayan M.S., Andjaparidze A.G., Savinskaya S.S. et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology. 1983; 20(1): 23-31. https://dx.doi.org/10.1159/000149370.
- Reyes G.R., Purdy M.A., Kim J.P. et al. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science. 1990; 247(4948): 1335-39. https://dx.doi.org/10.1126/science.2107574.
- Khuroo M.S. Discovery of hepatitis E: The epidemic non-A, non-B hepatitis 30 years down the memory lane. Virus Res. 2011; 161(1): 3-14. https://dx.doi.org/10.1016/j.virusres.2011.02.007.
- Albano L., Vasco M., Benincasa G. et al. Pathogenic mechanisms and current epidemiological status of HEV infection in asymptomatic blood donors and patients with chronic diseases. Eur J. Clin Microbiol Infect Dis. 2019; 38(7): 1203-9. https://dx.doi.org/10.1007/s10096-019-03534-x.
- Lhomme S., Marion O., Abravanel F. et al. Clinical manifestations, pathogenesis and treatment of hepatitis E. virus infections. J. Clin Med. 2020; 9(2): 331. https://dx.doi.org/10.3390/jcm9020331.
- Khuroo M.S., Khuroo M.S. Hepatitis E: An emerging global disease - from discovery towards control and cure. J. Viral Hepat. 2016; 23(2): 68-79. https://dx.doi.org/10.1111/jvh.12445.
- Gonzalez Tallo A.I., Vicente V.M., Lindemann M.L.M. [Chronic hepatitis E]. Med Clin (Barc). 2012; 138(2): 69-72. doi: https://dx.doi.org/10.1016/j.medcli.2011.02.003.
- Pischke S., Peron J-M., von Wulffen M. et al. Chronic hepatitis E. in rheumatology and internal medicine patients: A retrospective multicenter European cohort study. Viruses. 2019; 11(2): 186-96. https://dx.doi.org/10.3390/v11020186.
- Hansrivijit P., Trongtorsak A., Puthenpura M.M. et al. Hepatitis E. in solid organ transplant recipients: A systematic review and metaanalysis. World J. Gastroenterol. 2021; 27(12): 1240-54. https://dx.doi.org/10.3748/wjg.v27.i12.1240
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis E. virus infection. J. Hepatol. 2018; 68(6): 1256-71. https://dx.doi.org/10.1016/jjhep.2018.03.005.
- Клинические рекомендации. Лимфома Беркитта у взрослых. Национальное гематологическое общество. Российское профессиональное общество онкогематологов. 2016. Доступ: 2018/06/Limfoma-Berkitta-u-vzroslyh.pdf (дата обращения - 12.03.2022).
- Thomas E., Ghany M.G., Liang T.J. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother. 2012; 23(1): 1-12. https://dx.doi.org/10.3851/IMP2125.
- Deterding K., Grungreiff K., O. Lankisch T. et al. Gilbert's syndrome and antiviral therapy of hepatitis C. Ann Hepatol. 2009; 8(3): 246-50.
- Tamura A., Shimizu Y.K., Tanaka T. et al. Persistent infection of hepatitis E. virus transmitted by blood trans-fusion in a patient with T-cell lymphoma. Hepatol Res. 2007; 37(2): 113-20. https://dx.doi.org/10.1111/j.1872-034X.2007.00024.x.
- Kamar N., Rostaing L., Legrand-Abravanel F., Izopet J. How should hepatitis E. virus infection be defined in organ-transplant recipients? Am J. Transplant. 2013; 13(7): 1935-36. https://dx.doi.org/10.1111/ajt.12253.
- Gerolami R., Moal V., Colson P. Chronic hepatitis E. with cirrhosis in a kidney-transplant recipient. N. Engl J. Med. 2008; 358(8): 859-60. https://dx.doi.org/10.1056/NEJMc0708687.
- Kamar N., Garrouste C., Haagsma E.B. et al. Factors associated with chronic hepatitis in patients with hepatitis E. virus infection who have received solid organ transplants. Gastroenterology. 2011; 140(5): 1481-89. https://dx.doi.org/10.1053/j.gastro.2011.02.050.
- Rivero-Juarez A., Vallejo N., Lopez-Lopez P. et al. Ribavirin as a first treatment approach for hepatitis E. virus infection in transplant recipient patients. Microorganisms. 2020; 8(1): 51-64. https://dx.doi.org/10.3390/microorganisms8010051.
- Kamar N., Lhomme S., Abravanel F. et al. An early viral response predicts the virological response to ribavirin in hepatitis E. virus organ transplant patients. Transplantation 2015; 99(10): 2124-31. https://dx.doi.org/10.1097/TP.0000000000000850.
- Gorris M., van der Lecq B.M., van Erpecum K.J., de Bruijne J.J. Treatment for chronic hepatitis E. virus infection: A systematic review and meta-analysis. Viral Hepat. 2021; 28(3): 454-63. https://dx.doi.org/10.1111/jvh.13456.
- Abravanel F., Lhomme S., Rostaing L. et al. Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse. Clin Infect Dis. 2015; 60(1): 96-99. https://dx.doi.org/10.1093/cid/ciu742.
- Soon Ch.F., Behrendt P., Todt D. et al. Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T. cells against chronic hepatitis E. J. Hepatol. 2019; 71(4): 673-84. https://dx.doi.org/10.1016/j.jhep.2019.06.005.
- Debing Y., Gisa A., Dallmeier K. et al. A mutation in the hepatitis E. virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. Gastroenterology. 2014; 147(5):1008-11.e7; quiz e15-6. https://dx.doi.org/10.1053/j.gastro.2014.08.040.
- Todt D., Gisa A., Radonic A. et al. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E. virus genome. Gut. 2016; 65(10): 1733-43. https://dx.doi.org/10.1136/gutjnl-2015-311000.
- LeDesma R., Nimgaonkar I., Ploss A. Hepatitis E. virus replication. Viruses. 2019; 11(8): 719-21. https://dx.doi.org/10.3390/v11080719.
- Primadharsini P.P., Nagashima S., Okamoto H. Genetic Variability and Evolution of Hepatitis E. Virus. Viruses. 2019; 11(5):456. https://dx.doi.org/10.3390/v11050456.
- Horvatits T., zur Wiesch J.S., Lutgehetmann M. et al. The clinical perspective on hepatitis E. Viruses. 2019; 11(7): 617-36. https://dx.doi.org/10.3390/v11070617.
- Fraga M., Gouttenoire J., Sahli R. et al. Sofosbuvir add-on to ribavirin for chronic hepatitis E. in a cirrhotic liver transplant recipient: a case report. BMC Gastroenterol. 2019; 19(1): 76-78. https://dx.doi.org/10.1186/s12876-019-0995-z.
- Melgaco J.G., Gardinali N.R., da Motta de Mello V. et al. Hepatitis E: Update on prevention and control. Biomed Res Int. 2018; 2018: 5769201. https://dx.doi.org/10.1155/2018/5769201.